We then studied if EGFR-engineered CD8+ lymphocytes would have a better therapeutic effect on mice bearing PM299L tumors, a tumor cell line derived from fresh hepatic tumors induced in C57BL/6 mice as previously described (35). This evidence concerns the gene CD8A and neoplasm.